Understanding drug resistance in tuberculosis treatments in South Africa
Official title: Emergence of bedaquiline, pretomanid and linezolid resistance after implementation of new drug-resistant tuberculosis regimens in South Africa
Funded at Columbia University Health Sciences · NIH-10977076 · Data updated 2026-11-12
This study is looking at how some people with tuberculosis in South Africa might develop resistance to new medications like bedaquiline, pretomanid, and linezolid, so we can better understand how these drugs work and help improve treatment for everyone.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Columbia University Health Sciences NIH-funded |
| Lab location | 1 site (New York, United States) |
| Project start | November 25, 2022 |
| Project end | October 31, 2027 |
| Funding year | 2025 |
| Award (this year) | $722,084 |
| NIH project number | 5R01AI169938-03 |
| Project ID | NIH-10977076 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are individuals diagnosed with drug-resistant tuberculosis who are starting treatment with bedaquiline, pretomanid, or linezolid.
✕Less likely to help
Patients with drug-sensitive tuberculosis or those not receiving the specified treatments may not benefit from this research.
What this research studies
This research investigates how resistance to new tuberculosis medications, specifically bedaquiline, pretomanid, and linezolid, develops in patients undergoing treatment in South Africa. By observing patients receiving these drugs, the study aims to identify patterns of drug resistance that may emerge as these treatments become more widely used. The research will involve collecting data on patient outcomes and the genetic changes in the tuberculosis bacteria over time, helping to understand the dynamics of drug resistance in real-world settings.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for drug-resistant tuberculosis, enhancing cure rates and patient outcomes.
How similar studies have gone: Previous research has shown that understanding drug resistance patterns can significantly improve treatment outcomes, indicating that this approach has potential for success.
Where this research is happening
-
Columbia University Health Sciences
New York, United States Active
Researchers
- Principal investigator: Mathema, Barun — Columbia University Health Sciences
- Study coordinator: Mathema, Barun
Related research
Other NIH-funded projects on the same topics.
-
Coronary disease and immune activation in people with HIV and tuberculosis coinfection
This research looks at how having HIV and latent tuberculosis together might raise the risk of heart disease, and what immune changes are involved.
-
Pulmonary rehabilitation to reduce breathing problems after tuberculosis
A program of guided exercise and breathing training to help adults who have recovered from TB breathe better and feel healthier.
-
Pulmonary rehab to reduce breathing troubles after TB
A program of pulmonary rehabilitation is being studied to help adults who have completed TB treatment avoid ongoing lung problems and improve daily breathing.
-
Air pollution and tuberculosis spread in Kampala, Uganda
This project looks at whether dirty air from PM2.5 particles makes tuberculosis more likely to spread within urban slum households in Kampala, Uganda.
-
Air pollution and TB spread in Ugandan urban slums
This project explores whether exposure to air pollution makes tuberculosis more likely to spread within households in a crowded Ugandan slum.
-
Air pollution and TB transmission in Kampala’s urban slums
This project looks at whether air pollution from PM2.5 makes tuberculosis spread more easily from infected people to their neighbors in urban slums of Kampala, Uganda.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.